Naresh Mandava
Concepts (379)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Degeneration | 25 | 2026 | 196 | 5.540 |
Why?
| | Geographic Atrophy | 15 | 2026 | 105 | 5.130 |
Why?
| | Wet Macular Degeneration | 9 | 2026 | 63 | 2.870 |
Why?
| | Tomography, Optical Coherence | 19 | 2026 | 283 | 2.700 |
Why?
| | Visual Acuity | 22 | 2026 | 499 | 2.310 |
Why?
| | Fluorescein Angiography | 21 | 2026 | 197 | 2.240 |
Why?
| | Retinal Detachment | 6 | 2023 | 74 | 1.880 |
Why?
| | Diabetic Retinopathy | 11 | 2023 | 211 | 1.670 |
Why?
| | Retinal Drusen | 4 | 2024 | 31 | 1.660 |
Why?
| | Complement System Proteins | 4 | 2026 | 326 | 1.630 |
Why?
| | Angiogenesis Inhibitors | 17 | 2023 | 239 | 1.590 |
Why?
| | Registries | 9 | 2025 | 2400 | 1.510 |
Why?
| | Choroid | 7 | 2025 | 81 | 1.440 |
Why?
| | Complement Activation | 5 | 2025 | 412 | 1.170 |
Why?
| | Vitreous Body | 16 | 2022 | 118 | 1.080 |
Why?
| | Vitrectomy | 12 | 2020 | 74 | 1.000 |
Why?
| | Multimodal Imaging | 2 | 2025 | 137 | 0.950 |
Why?
| | Macula Lutea | 2 | 2023 | 21 | 0.940 |
Why?
| | Vascular Endothelial Growth Factor A | 13 | 2024 | 545 | 0.940 |
Why?
| | Aged, 80 and over | 24 | 2026 | 8391 | 0.920 |
Why?
| | Biomarkers | 9 | 2026 | 4340 | 0.810 |
Why?
| | Retina | 10 | 2021 | 330 | 0.800 |
Why?
| | Follow-Up Studies | 19 | 2026 | 5439 | 0.780 |
Why?
| | Retinal Diseases | 4 | 2023 | 102 | 0.750 |
Why?
| | Antibodies, Monoclonal | 9 | 2011 | 1512 | 0.720 |
Why?
| | Aged | 37 | 2026 | 26432 | 0.710 |
Why?
| | Retinal Neovascularization | 2 | 2019 | 29 | 0.690 |
Why?
| | Choroidal Neovascularization | 6 | 2019 | 57 | 0.670 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.660 |
Why?
| | Retinal Perforations | 4 | 2015 | 18 | 0.640 |
Why?
| | Quarantine | 1 | 2020 | 31 | 0.620 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 144 | 0.560 |
Why?
| | Retinitis Pigmentosa | 3 | 2021 | 22 | 0.540 |
Why?
| | Retinopathy of Prematurity | 4 | 2024 | 183 | 0.540 |
Why?
| | Fundus Oculi | 8 | 2026 | 89 | 0.530 |
Why?
| | Humans | 89 | 2026 | 146342 | 0.520 |
Why?
| | Female | 57 | 2026 | 79499 | 0.520 |
Why?
| | Male | 55 | 2026 | 73396 | 0.510 |
Why?
| | Disease Progression | 8 | 2026 | 2867 | 0.500 |
Why?
| | Epiretinal Membrane | 3 | 2010 | 7 | 0.490 |
Why?
| | Intraocular Pressure | 6 | 2012 | 344 | 0.480 |
Why?
| | Automobile Driving | 1 | 2018 | 157 | 0.480 |
Why?
| | Prospective Studies | 10 | 2026 | 8123 | 0.480 |
Why?
| | Fovea Centralis | 3 | 2025 | 24 | 0.470 |
Why?
| | Scleral Buckling | 3 | 2019 | 16 | 0.450 |
Why?
| | Proliferating Cell Nuclear Antigen | 2 | 2007 | 48 | 0.450 |
Why?
| | Vitreoretinopathy, Proliferative | 2 | 2007 | 15 | 0.440 |
Why?
| | Optic Neuropathy, Ischemic | 3 | 2013 | 31 | 0.420 |
Why?
| | RNA, Catalytic | 2 | 2007 | 191 | 0.410 |
Why?
| | Surveys and Questionnaires | 6 | 2026 | 6073 | 0.410 |
Why?
| | Self Report | 1 | 2018 | 870 | 0.410 |
Why?
| | Recombinant Fusion Proteins | 4 | 2013 | 663 | 0.390 |
Why?
| | Middle Aged | 35 | 2026 | 36619 | 0.390 |
Why?
| | Antibodies, Monoclonal, Humanized | 11 | 2015 | 992 | 0.380 |
Why?
| | Optic Disk | 4 | 2025 | 57 | 0.380 |
Why?
| | Research Design | 1 | 2019 | 1143 | 0.370 |
Why?
| | Bevacizumab | 11 | 2015 | 169 | 0.370 |
Why?
| | Retinal Necrosis Syndrome, Acute | 2 | 2013 | 7 | 0.350 |
Why?
| | Retrospective Studies | 26 | 2025 | 17438 | 0.350 |
Why?
| | Retinal Vein Occlusion | 2 | 2015 | 14 | 0.350 |
Why?
| | Image Processing, Computer-Assisted | 3 | 2026 | 778 | 0.350 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.340 |
Why?
| | Photography | 4 | 2015 | 120 | 0.340 |
Why?
| | Retinal Pigment Epithelium | 3 | 2024 | 81 | 0.340 |
Why?
| | Uveal Diseases | 2 | 2013 | 6 | 0.340 |
Why?
| | Endophthalmitis | 3 | 2017 | 46 | 0.330 |
Why?
| | Colorado | 8 | 2025 | 4595 | 0.330 |
Why?
| | Cross-Sectional Studies | 8 | 2025 | 5899 | 0.330 |
Why?
| | Cataract | 2 | 2020 | 240 | 0.320 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2015 | 55 | 0.310 |
Why?
| | Complement Factor B | 2 | 2022 | 106 | 0.310 |
Why?
| | Glycogen Storage Disease Type IIb | 2 | 2007 | 27 | 0.300 |
Why?
| | Visual Fields | 3 | 2022 | 120 | 0.300 |
Why?
| | Vision, Low | 4 | 2022 | 16 | 0.290 |
Why?
| | Pigment Epithelium of Eye | 2 | 2006 | 36 | 0.290 |
Why?
| | Injections | 6 | 2010 | 201 | 0.280 |
Why?
| | Ophthalmology | 2 | 2013 | 122 | 0.270 |
Why?
| | Risk Factors | 11 | 2025 | 10921 | 0.270 |
Why?
| | Ocular Hypertension | 1 | 2009 | 72 | 0.270 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2014 | 1408 | 0.270 |
Why?
| | Phacoemulsification | 3 | 2020 | 124 | 0.260 |
Why?
| | Macular Edema | 2 | 2015 | 49 | 0.250 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2007 | 21 | 0.250 |
Why?
| | Optic Nerve Injuries | 1 | 2007 | 9 | 0.250 |
Why?
| | Quantum Dots | 2 | 2021 | 37 | 0.250 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.250 |
Why?
| | Papilledema | 1 | 2007 | 44 | 0.250 |
Why?
| | Glaucoma | 3 | 2025 | 267 | 0.250 |
Why?
| | Glucocorticoids | 2 | 2013 | 536 | 0.250 |
Why?
| | Vision Disorders | 2 | 2022 | 179 | 0.240 |
Why?
| | Puerperal Disorders | 1 | 2007 | 35 | 0.240 |
Why?
| | Triamcinolone Acetonide | 1 | 2006 | 20 | 0.240 |
Why?
| | Ocular Hypotension | 1 | 2006 | 10 | 0.240 |
Why?
| | Herpesvirus 1, Human | 1 | 2007 | 87 | 0.230 |
Why?
| | Ciliary Body | 1 | 2006 | 40 | 0.230 |
Why?
| | Myopia | 1 | 2006 | 59 | 0.230 |
Why?
| | Telangiectasis | 1 | 2005 | 7 | 0.230 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 40 | 0.220 |
Why?
| | Granuloma | 1 | 2006 | 96 | 0.220 |
Why?
| | Optical Imaging | 1 | 2026 | 63 | 0.220 |
Why?
| | Time Factors | 5 | 2025 | 7109 | 0.220 |
Why?
| | Sickness Impact Profile | 2 | 2026 | 67 | 0.220 |
Why?
| | DNA, Viral | 1 | 2007 | 354 | 0.220 |
Why?
| | Retinal Vessels | 1 | 2005 | 79 | 0.210 |
Why?
| | Retinal Ganglion Cells | 4 | 2022 | 124 | 0.210 |
Why?
| | Fluorocarbons | 1 | 2005 | 122 | 0.200 |
Why?
| | Diseases in Twins | 1 | 2024 | 115 | 0.200 |
Why?
| | Laser Therapy | 2 | 2021 | 146 | 0.200 |
Why?
| | Birth Weight | 2 | 2024 | 521 | 0.200 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 1101 | 0.200 |
Why?
| | Vision Tests | 1 | 2023 | 22 | 0.200 |
Why?
| | Twins | 1 | 2024 | 156 | 0.200 |
Why?
| | Temporal Arteries | 2 | 2015 | 45 | 0.200 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 3 | 2013 | 109 | 0.190 |
Why?
| | Hemianopsia | 1 | 2022 | 11 | 0.190 |
Why?
| | Disease Models, Animal | 4 | 2012 | 4580 | 0.180 |
Why?
| | Ophthalmoscopy | 2 | 2015 | 38 | 0.170 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 8 | 0.170 |
Why?
| | Longitudinal Studies | 2 | 2026 | 3017 | 0.170 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.170 |
Why?
| | Capsule Opacification | 1 | 2021 | 22 | 0.170 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.170 |
Why?
| | Ranibizumab | 5 | 2013 | 21 | 0.160 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.160 |
Why?
| | Herpesvirus 3, Human | 2 | 2015 | 342 | 0.160 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3416 | 0.150 |
Why?
| | Nerve Fibers | 2 | 2010 | 105 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2025 | 389 | 0.150 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 147 | 0.150 |
Why?
| | Electrodes, Implanted | 2 | 2018 | 114 | 0.150 |
Why?
| | Machine Learning | 1 | 2026 | 594 | 0.150 |
Why?
| | Intravitreal Injections | 6 | 2020 | 73 | 0.150 |
Why?
| | Quality of Life | 5 | 2026 | 3200 | 0.150 |
Why?
| | Protective Factors | 1 | 2019 | 97 | 0.150 |
Why?
| | Odds Ratio | 2 | 2019 | 1077 | 0.150 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.150 |
Why?
| | Ischemia | 2 | 2017 | 421 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 40 | 0.140 |
Why?
| | C-Reactive Protein | 1 | 2021 | 429 | 0.140 |
Why?
| | Intraoperative Complications | 1 | 2020 | 157 | 0.140 |
Why?
| | Visual Prosthesis | 1 | 2018 | 1 | 0.140 |
Why?
| | Cohort Studies | 5 | 2020 | 6077 | 0.130 |
Why?
| | Metformin | 1 | 2021 | 328 | 0.130 |
Why?
| | Orbit | 2 | 2010 | 67 | 0.130 |
Why?
| | Anterior Eye Segment | 1 | 2017 | 10 | 0.130 |
Why?
| | Labor, Induced | 1 | 2017 | 41 | 0.120 |
Why?
| | Gestational Age | 4 | 2024 | 990 | 0.120 |
Why?
| | Labor, Obstetric | 1 | 2017 | 67 | 0.120 |
Why?
| | Giant Cell Arteritis | 2 | 2015 | 48 | 0.120 |
Why?
| | Strabismus | 1 | 2017 | 71 | 0.120 |
Why?
| | Laser Coagulation | 3 | 2012 | 80 | 0.120 |
Why?
| | Postoperative Complications | 3 | 2021 | 3034 | 0.120 |
Why?
| | Retinal Degeneration | 2 | 2015 | 40 | 0.120 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2017 | 91 | 0.120 |
Why?
| | Blindness | 3 | 2013 | 51 | 0.110 |
Why?
| | Gyrate Atrophy | 1 | 2015 | 2 | 0.110 |
Why?
| | Phenotype | 3 | 2022 | 3206 | 0.110 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 829 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1543 | 0.110 |
Why?
| | Vitreoretinal Surgery | 1 | 2015 | 4 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2020 | 3647 | 0.110 |
Why?
| | Vitreous Detachment | 1 | 2015 | 6 | 0.110 |
Why?
| | Recovery of Function | 1 | 2019 | 725 | 0.110 |
Why?
| | Needles | 1 | 2015 | 61 | 0.110 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.110 |
Why?
| | Incidence | 2 | 2020 | 2936 | 0.110 |
Why?
| | Biopsy, Needle | 1 | 2015 | 183 | 0.110 |
Why?
| | Eye Infections, Bacterial | 1 | 2015 | 46 | 0.110 |
Why?
| | Rats, Inbred BN | 3 | 2011 | 56 | 0.100 |
Why?
| | Antiviral Agents | 2 | 2013 | 779 | 0.100 |
Why?
| | Logistic Models | 1 | 2019 | 2126 | 0.100 |
Why?
| | Proteins | 1 | 2020 | 1022 | 0.100 |
Why?
| | Wounds, Gunshot | 2 | 2010 | 262 | 0.100 |
Why?
| | Treatment Outcome | 7 | 2021 | 11821 | 0.100 |
Why?
| | Oculomotor Muscles | 1 | 2014 | 86 | 0.100 |
Why?
| | Inflammation | 3 | 2023 | 2919 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 2 | 2021 | 474 | 0.100 |
Why?
| | Drug Packaging | 2 | 2011 | 41 | 0.100 |
Why?
| | Uvea | 1 | 2013 | 4 | 0.100 |
Why?
| | Exchange Transfusion, Whole Blood | 1 | 2013 | 18 | 0.100 |
Why?
| | Uveomeningoencephalitic Syndrome | 1 | 2013 | 7 | 0.100 |
Why?
| | Fibrin | 1 | 2014 | 84 | 0.100 |
Why?
| | Retinal Artery Occlusion | 1 | 2013 | 10 | 0.100 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2013 | 10 | 0.100 |
Why?
| | Tendons | 1 | 2014 | 136 | 0.100 |
Why?
| | Proteomics | 1 | 2020 | 1203 | 0.100 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2013 | 22 | 0.100 |
Why?
| | Isoxazoles | 1 | 2013 | 57 | 0.090 |
Why?
| | Lymphoproliferative Disorders | 1 | 2013 | 59 | 0.090 |
Why?
| | Premature Birth | 1 | 2017 | 390 | 0.090 |
Why?
| | Silicon | 1 | 2012 | 19 | 0.090 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2014 | 145 | 0.090 |
Why?
| | Lens Subluxation | 1 | 2012 | 4 | 0.090 |
Why?
| | Trabecular Meshwork | 1 | 2013 | 74 | 0.090 |
Why?
| | Viremia | 1 | 2013 | 158 | 0.090 |
Why?
| | Adult | 15 | 2020 | 41087 | 0.090 |
Why?
| | Exanthema | 1 | 2013 | 86 | 0.090 |
Why?
| | Uveitis, Posterior | 1 | 2012 | 12 | 0.090 |
Why?
| | Electric Stimulation Therapy | 1 | 2012 | 63 | 0.090 |
Why?
| | Fluocinolone Acetonide | 1 | 2012 | 14 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 340 | 0.090 |
Why?
| | Diagnosis, Differential | 4 | 2013 | 1503 | 0.090 |
Why?
| | Microsurgery | 1 | 2012 | 75 | 0.090 |
Why?
| | Placenta | 1 | 2018 | 794 | 0.080 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2011 | 77 | 0.080 |
Why?
| | Fluorescein-5-isothiocyanate | 2 | 2009 | 34 | 0.080 |
Why?
| | Electroretinography | 2 | 2012 | 51 | 0.080 |
Why?
| | Drug Storage | 1 | 2011 | 52 | 0.080 |
Why?
| | Dextrans | 2 | 2009 | 83 | 0.080 |
Why?
| | Particulate Matter | 2 | 2011 | 328 | 0.080 |
Why?
| | Global Health | 1 | 2014 | 403 | 0.080 |
Why?
| | Dissection | 1 | 2011 | 58 | 0.080 |
Why?
| | Health Care Costs | 1 | 2014 | 423 | 0.080 |
Why?
| | Silicone Oils | 1 | 2011 | 42 | 0.080 |
Why?
| | Antioxidants | 1 | 2014 | 544 | 0.080 |
Why?
| | Infliximab | 2 | 2007 | 107 | 0.080 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 2 | 2007 | 32 | 0.080 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 449 | 0.080 |
Why?
| | Protein Multimerization | 1 | 2011 | 201 | 0.080 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2009 | 74 | 0.070 |
Why?
| | Bacteria | 1 | 2015 | 766 | 0.070 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2009 | 49 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2013 | 324 | 0.070 |
Why?
| | Herpes Zoster | 1 | 2013 | 318 | 0.070 |
Why?
| | Tonometry, Ocular | 1 | 2009 | 107 | 0.070 |
Why?
| | Scotoma | 1 | 2008 | 6 | 0.070 |
Why?
| | Rats | 4 | 2012 | 5586 | 0.070 |
Why?
| | United States | 3 | 2020 | 16136 | 0.070 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 253 | 0.070 |
Why?
| | Algorithms | 2 | 2026 | 1849 | 0.070 |
Why?
| | Retinal Artery | 1 | 2007 | 17 | 0.070 |
Why?
| | Vitreous Hemorrhage | 1 | 2007 | 10 | 0.060 |
Why?
| | Cerebral Angiography | 1 | 2007 | 121 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2007 | 2791 | 0.060 |
Why?
| | Acyclovir | 1 | 2007 | 97 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2009 | 2022 | 0.060 |
Why?
| | Frameshift Mutation | 1 | 2006 | 32 | 0.060 |
Why?
| | Conjunctival Neoplasms | 1 | 2005 | 9 | 0.060 |
Why?
| | Internationality | 2 | 2018 | 156 | 0.060 |
Why?
| | Ultrasonography | 2 | 2007 | 788 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2007 | 248 | 0.060 |
Why?
| | Eye Injuries, Penetrating | 1 | 2005 | 19 | 0.060 |
Why?
| | Indocyanine Green | 1 | 2005 | 43 | 0.060 |
Why?
| | Eye Foreign Bodies | 1 | 2005 | 23 | 0.060 |
Why?
| | beta-Thalassemia | 1 | 2006 | 40 | 0.060 |
Why?
| | Coloring Agents | 1 | 2005 | 88 | 0.060 |
Why?
| | Animals | 7 | 2014 | 38106 | 0.060 |
Why?
| | Eye Injuries | 1 | 2006 | 53 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2007 | 1224 | 0.060 |
Why?
| | Staining and Labeling | 1 | 2005 | 148 | 0.060 |
Why?
| | Uncertainty | 1 | 2026 | 145 | 0.050 |
Why?
| | Infant, Newborn | 3 | 2024 | 6460 | 0.050 |
Why?
| | Uveitis | 1 | 2006 | 152 | 0.050 |
Why?
| | Antihypertensive Agents | 1 | 2009 | 519 | 0.050 |
Why?
| | Mydriatics | 1 | 2004 | 10 | 0.050 |
Why?
| | Metals | 1 | 2005 | 137 | 0.050 |
Why?
| | Pupil | 1 | 2004 | 21 | 0.050 |
Why?
| | Pregnancy | 3 | 2018 | 7230 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1031 | 0.050 |
Why?
| | Sclera | 2 | 2014 | 39 | 0.050 |
Why?
| | Hospitals, County | 1 | 2023 | 11 | 0.050 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2007 | 357 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2008 | 1998 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2026 | 295 | 0.050 |
Why?
| | Observer Variation | 1 | 2004 | 356 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 846 | 0.050 |
Why?
| | Fibroblasts | 2 | 2013 | 1034 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2026 | 1331 | 0.050 |
Why?
| | Chimera | 1 | 2002 | 62 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 207 | 0.050 |
Why?
| | Enzyme Stability | 1 | 2002 | 74 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Endopeptidases | 1 | 2002 | 80 | 0.050 |
Why?
| | Preventive Medicine | 1 | 2002 | 38 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2007 | 2070 | 0.050 |
Why?
| | Young Adult | 6 | 2019 | 14330 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 41 | 0.040 |
Why?
| | Blood | 1 | 2002 | 107 | 0.040 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 467 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2002 | 245 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 120 | 0.040 |
Why?
| | Retreatment | 2 | 2012 | 79 | 0.040 |
Why?
| | Rabbits | 1 | 2002 | 651 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 182 | 0.040 |
Why?
| | Lenses, Intraocular | 1 | 2021 | 49 | 0.040 |
Why?
| | Cell Division | 1 | 2002 | 736 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2013 | 4118 | 0.040 |
Why?
| | Equipment Design | 2 | 2014 | 520 | 0.040 |
Why?
| | Drug Compounding | 2 | 2011 | 106 | 0.040 |
Why?
| | Electric Stimulation | 1 | 2021 | 273 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 244 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1827 | 0.040 |
Why?
| | Cell Survival | 2 | 2013 | 1105 | 0.040 |
Why?
| | Melanoma | 1 | 2005 | 765 | 0.040 |
Why?
| | Postoperative Period | 1 | 2019 | 355 | 0.030 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.030 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 1271 | 0.030 |
Why?
| | Infant | 3 | 2020 | 10114 | 0.030 |
Why?
| | Primary Health Care | 1 | 2008 | 1776 | 0.030 |
Why?
| | Prevalence | 2 | 2015 | 2861 | 0.030 |
Why?
| | Iris Diseases | 1 | 2017 | 7 | 0.030 |
Why?
| | Choroid Diseases | 1 | 2017 | 10 | 0.030 |
Why?
| | Lipids | 1 | 2002 | 714 | 0.030 |
Why?
| | Prosthesis Implantation | 1 | 2018 | 156 | 0.030 |
Why?
| | Parity | 1 | 2017 | 113 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 154 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 801 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 881 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 779 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2015 | 30 | 0.030 |
Why?
| | Risk | 1 | 2018 | 920 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 90 | 0.030 |
Why?
| | Endotamponade | 1 | 2015 | 3 | 0.030 |
Why?
| | Myopia, Degenerative | 1 | 2015 | 5 | 0.030 |
Why?
| | Tenon Capsule | 1 | 2014 | 3 | 0.030 |
Why?
| | Tissue Adhesions | 1 | 2015 | 32 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 50 | 0.030 |
Why?
| | Conjunctiva | 1 | 2014 | 52 | 0.030 |
Why?
| | Atrophy | 1 | 2015 | 199 | 0.030 |
Why?
| | Biometry | 1 | 2014 | 67 | 0.030 |
Why?
| | Lens Implantation, Intraocular | 1 | 2015 | 80 | 0.030 |
Why?
| | Adolescent | 3 | 2012 | 22557 | 0.030 |
Why?
| | Fetus | 1 | 2018 | 800 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2014 | 251 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2022 | 2012 | 0.020 |
Why?
| | Safety-net Providers | 1 | 2014 | 133 | 0.020 |
Why?
| | Adaptation, Ocular | 1 | 2012 | 6 | 0.020 |
Why?
| | Dark Adaptation | 1 | 2012 | 13 | 0.020 |
Why?
| | Rats, Mutant Strains | 1 | 2012 | 19 | 0.020 |
Why?
| | Sclerostomy | 1 | 2012 | 4 | 0.020 |
Why?
| | Infant, Premature | 1 | 2017 | 622 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2013 | 172 | 0.020 |
Why?
| | Cell Count | 1 | 2012 | 315 | 0.020 |
Why?
| | Child, Preschool | 1 | 2007 | 11913 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 772 | 0.020 |
Why?
| | Drug Implants | 1 | 2012 | 83 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1412 | 0.020 |
Why?
| | Gold | 1 | 2012 | 118 | 0.020 |
Why?
| | Bruch Membrane | 1 | 2011 | 8 | 0.020 |
Why?
| | Swine | 1 | 2014 | 821 | 0.020 |
Why?
| | Polyglycolic Acid | 1 | 2011 | 44 | 0.020 |
Why?
| | Miniaturization | 1 | 2011 | 22 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 872 | 0.020 |
Why?
| | Drug Stability | 1 | 2011 | 172 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2011 | 192 | 0.020 |
Why?
| | Chromatography, Gel | 1 | 2010 | 131 | 0.020 |
Why?
| | Fluorescein | 1 | 2010 | 23 | 0.020 |
Why?
| | Immunoglobulin Light Chains | 1 | 2010 | 52 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2010 | 83 | 0.020 |
Why?
| | Molecular Weight | 1 | 2010 | 295 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1665 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 326 | 0.020 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2010 | 80 | 0.020 |
Why?
| | Aptamers, Nucleotide | 1 | 2010 | 88 | 0.020 |
Why?
| | Lactic Acid | 1 | 2011 | 295 | 0.020 |
Why?
| | Particle Size | 1 | 2011 | 386 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 796 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 43 | 0.020 |
Why?
| | Community Health Centers | 1 | 2008 | 59 | 0.020 |
Why?
| | Optic Nerve Diseases | 1 | 2008 | 49 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2010 | 340 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 970 | 0.020 |
Why?
| | Models, Biological | 1 | 2015 | 1761 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 2013 | 735 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2011 | 650 | 0.010 |
Why?
| | Pilot Projects | 1 | 2012 | 1888 | 0.010 |
Why?
| | Imaging, Three-Dimensional | 1 | 2010 | 582 | 0.010 |
Why?
| | Pedigree | 1 | 2007 | 512 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 432 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 486 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1942 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2921 | 0.010 |
Why?
| | Mass Screening | 1 | 2008 | 1307 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2786 | 0.010 |
Why?
| | Risk Assessment | 1 | 2008 | 3712 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2623 | 0.010 |
Why?
| | Aging | 1 | 2008 | 1996 | 0.010 |
Why?
| | Mutation | 1 | 2007 | 4093 | 0.010 |
Why?
| | Child | 1 | 2012 | 22693 | 0.010 |
Why?
|
|
Mandava's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|